We are grateful for external funding from The Research Council of Norway, Norwegian Cancer Society, South-Eastern Norway Regional Health Authority and EU.
Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan RP, Ngo LT, Hofgaard PO, Heinzelbecker J, Bobic S, Fossum E, Spång HCL, Braathen R, Bogen B(2023) Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM J Immunother Cancer, 11(8) DOI 10.1136/jitc-2023-006944, PubMed 37607769
Métivier C, Le Saëc P, Gaschet J, Chauvet C, Marionneau-Lambot S, Hofgaard PO, Bogen B, Pineau J, Le Bris N, Tripier R, Alliot C, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L(2023) Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma Pharmaceutics, 15(7) DOI 10.3390/pharmaceutics15071817, PubMed 37514004
Vikse EL, Fossum E, Erdal MS, Hungnes O, Bragstad K(2023) Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022 Influenza Other Respir Viruses, 17(6), e13144 DOI 10.1111/irv.13144, PubMed 37273461